Androgel (testosterone)
Androderm (testosterone)
Axiron (testosterone)
Bio-T-Gel (testosterone)
Delatestryl (testosterone enanthate)
Depo-Testosternone (testosterone cypionate)
Fortesta (testosterone)
Striant (testosterone)
Testim (testosterone)
Testopel (testosterone)

Drug Class


Indication for Use

Hormone replacement


Heart attack
Myocardial infarction
Congestive heart failure
Pulmonary embolism
Deep vein thrombosis (DVT)


Testosterone therapy was approved by the FDA starting in approximately 2000 to treat conditions related to hypogonadism, a condition associated with genetic disorders or procedures such as chemotherapy. However, manufacturers of the product have created their own disease of “low testosterone” to market their product as a treatment for a wide variety of symptoms related to aging.

Testosterone therapy is most often administered as a gel, patch, or injection. The market leaders are Androgel and Axiron.

Recent studies have linked testosterone treatments to an increased risk of heart attack, myocardial infarction, congestive heart failure, stroke, pulmonary embolism, deep vein thrombosis, and death. Individual cases have been filed against the manufacturers of testosterone therapy low products in a variety of state and federal court venues across the country.